Does Ozempic Cause Cancer? Separating the Boxed Warning, the Rodent Data, and the Human Evidence

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Topic: oncologic safety of semaglutide

Key Takeaways

• The FDA boxed warning for Ozempic flags thyroid C-cell tumors observed in rodent studies, not confirmed cancer cases in humans
• Large human epidemiologic studies have not identified a clear increase in thyroid cancer or pancreatic cancer in GLP-1 users compared to similar patients on other treatments
• Ozempic is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2)
• Weight loss itself reduces the risk of multiple obesity-related cancers; the net cancer effect of Ozempic in eligible patients may be neutral or favorable
• Active surveillance continues across pharmacovigilance systems; the question is not closed, but the human evidence to date is largely reassuring

Direct answer

Ozempic has not been shown to cause cancer in humans at typical clinical doses. The FDA boxed warning reflects thyroid C-cell tumor findings in rats and mice that have never been clearly reproduced in human populations. Large epidemiologic studies, including a 2024 JAMA paper covering tens of thousands of GLP-1 patients, have not found a statistically meaningful increase in thyroid cancer. Pancreatic cancer signals raised earlier in the drug class have not held up under repeated rigorous study. The contraindications matter: patients with personal or family history of medullary thyroid cancer or MEN-2 should not use Ozempic. For everyone else, current evidence does not support cancer fear as a reason to avoid the medication.

Table of contents

1. The boxed warning and what it actually says
2. Why rodent data prompted the warning
3. The human thyroid cancer evidence
4. The pancreatic cancer question
5. The contraindications you need to know
6. Obesity, weight loss, and the cancers GLP-1 might reduce
7. What the FDA, EMA, and clinical societies say now
8. Decision framework: who should worry, who should not
9. The contrary view: reasons to retain caution
10. FAQ
11. Sources

The boxed warning and what it actually says

Ozempic's FDA prescribing information includes a boxed warning, the agency's most prominent safety alert. The warning states that semaglutide causes thyroid C-cell tumors in rodents and that it is unknown whether the medication causes thyroid C-cell tumors in humans, including medullary thyroid carcinoma (MTC). The warning lists MTC and MEN-2 as contraindications.

Two things to notice. First, the warning is honest about uncertainty: it does not say semaglutide causes cancer in humans, only that it causes tumors in rodents and that human risk is unknown. Second, the warning translates directly into a clinical action: do not prescribe semaglutide to patients with MTC or MEN-2 history.

The boxed warning has not changed since semaglutide's approval. It applies to all GLP-1 receptor agonists in the United States that carry the class warning, including liraglutide, dulaglutide, semaglutide, and tirzepatide.

Why rodent data prompted the warning

In preclinical toxicology studies, rats and mice exposed to long-term GLP-1 receptor agonist therapy developed thyroid C-cell hyperplasia and, with higher cumulative exposure, C-cell adenomas and carcinomas. The findings were dose-dependent and consistent across species.

Several features of the rodent finding limit direct extrapolation to humans:

• Rodent thyroid glands contain far more C-cells than human thyroid glands, on a per-gland basis
• Rodent C-cells are more responsive to GLP-1 receptor stimulation than human C-cells
• The dose-time exposures in the studies far exceed typical human clinical use
• Some other species (monkeys) did not develop the same tumors at clinically relevant exposures

The FDA's posture was conservative: require the warning and contraindications, then watch human post-marketing data carefully. That has been the operative approach since liraglutide's 2010 approval and remains so now.

The human thyroid cancer evidence

The available human evidence comes from several sources: post-marketing pharmacovigilance reports, observational claims-database studies, clinical trial data, and meta-analyses.

Pharmacovigilance. The FDA Adverse Event Reporting System (FAERS) has accumulated thyroid cancer reports in GLP-1 users since the early 2010s. FAERS data are subject to reporting bias and cannot establish causation. They can flag signals worth studying further.

Claims database studies. Large U.S. and European studies have compared thyroid cancer rates in GLP-1 users to matched controls on other diabetes treatments. The 2024 Wang et al. JAMA paper using SEER-Medicare data found no statistically significant increase in thyroid cancer among GLP-1 users compared to comparable patients. Some smaller European cohort studies found borderline signals; others did not.

Trial data. Pooled analyses of the SUSTAIN trial program and SELECT did not identify a meaningful excess of thyroid cancers in semaglutide-treated patients. Trial durations are limited (typically 1-3 years), so very long-latency effects could be missed.

Meta-analyses. Multiple systematic reviews have concluded that the human evidence does not currently support a causal link between GLP-1 use and thyroid cancer at clinically relevant doses, while acknowledging the limitations of available data.

The pancreatic cancer question

Pancreatic cancer was an early concern in the GLP-1 class. The receptor is expressed in pancreatic ductal tissue, acute pancreatitis is a documented adverse event for the class, and case reports of pancreatic cancer in GLP-1 users appeared shortly after market entry. The FDA opened an investigation in 2013.

Subsequent large studies have not confirmed an increased risk. A series of analyses using major U.S. and European claims databases, randomized trial extension data, and pooled meta-analyses have produced consistently null or slightly favorable findings. The most influential included the LEADER trial extension for liraglutide and pooled analyses across the SUSTAIN and PIONEER programs for semaglutide.

The current scientific consensus is that GLP-1 receptor agonists do not appear to increase pancreatic cancer risk. The signal that prompted the initial concern likely reflected detection bias (patients newly diagnosed with diabetes are more likely to be evaluated and to have early pancreatic cancer detected) and the inherent challenges of small early observational datasets.

The contraindications you need to know

The prescribing information lists clear contraindications. These are not advisory; they are absolute or strong relative contraindications.

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC in a first-degree relative
• Multiple endocrine neoplasia type 2 (MEN-2) syndrome
• Known hypersensitivity to semaglutide or its excipients

Other situations that warrant discussion but are not absolute contraindications include recent history of pancreatitis, severe gastrointestinal disease, history of certain other cancers, and pregnancy or planning pregnancy. These are case-by-case decisions for your prescriber.

The MTC and MEN-2 contraindications matter because medullary thyroid carcinoma is a rare cancer of thyroid C-cells, the same cell type that proliferated in rodent studies. Patients with family history may carry RET mutations that predispose to MTC, and any added risk from GLP-1 use would be unacceptable.

Obesity, weight loss, and the cancers GLP-1 might reduce

The cancer conversation about Ozempic has a side that often gets ignored. Obesity is a well-established risk factor for at least 13 cancers including endometrial, esophageal, kidney, pancreatic, colorectal, postmenopausal breast, ovarian, gallbladder, liver, gastric cardia, multiple myeloma, meningioma, and thyroid cancer itself. Weight loss reduces the risk of several of these.

Observational analyses of GLP-1 users have suggested possible reductions in obesity-related cancers compared to non-users. The 2024 SELECT trial extension data and parallel claims database studies have produced signals suggestive of lower cancer incidence in the GLP-1 cohort. Confounding makes interpretation difficult: patients on GLP-1 medications differ from non-users in many ways beyond the medication itself.

The plausible biological story is that weight loss reduces obesity-related cancer risk and that GLP-1 medications may have additional direct effects on inflammation, insulin signaling, and tumor microenvironment that could be net protective. None of this is established. It is an active research area.

What this means practically: the cancer accounting for Ozempic is not simply "boxed warning therefore risky." For eligible patients with obesity, the medication may be neutral or favorable for total cancer risk because the obesity reduction itself reduces risk. This does not erase the MTC contraindications, but it does change the overall framing.

What the FDA, EMA, and clinical societies say now

The FDA maintains the boxed warning and contraindications. The agency continues to monitor pharmacovigilance data and has not, as of May 2026, issued additional cancer warnings beyond the existing label.

The European Medicines Agency has reached a similar position. Periodic safety updates have not led to additional cancer-related label changes.

The American Diabetes Association 2025 Standards of Care continue to recommend semaglutide as a preferred agent in eligible patients without contraindications. The Endocrine Society and the American Association of Clinical Endocrinology have published similar positions.

The Obesity Society and similar bodies have endorsed semaglutide and tirzepatide for chronic weight management with the standard contraindications observed.

Decision framework: who should worry, who should not

Do not use Ozempic if:

• You have personal history of MTC
• You have first-degree family history of MTC
• You have known MEN-2
• You have an unexplained thyroid mass under evaluation

Discuss carefully with your prescriber and oncologist if:

• You have other thyroid cancer history (papillary, follicular)
• You have pancreatic cancer history or strong family history
• You have a current active cancer of any type
• You have a recent history of severe pancreatitis

Standard use is reasonable if:

• You meet FDA indications (type 2 diabetes for Ozempic, obesity for Wegovy)
• You have no contraindications listed above
• You understand the boxed warning is based on rodent data, not human findings
• You commit to reporting new symptoms (neck lumps, hoarseness, persistent abdominal pain)

The contrary view: reasons to retain caution

The strongest arguments for continued caution despite reassuring human data:

Latency. Many cancers develop over decades. Semaglutide has been on the U.S. market since 2017 in widespread use. The full long-latency cancer profile is not yet visible. Reassuring 5-year data does not rule out 20-year findings.

Reporting bias. Pharmacovigilance systems and even claims databases miss cases. The true magnitude of any signal could be larger than visible if certain cancer types are underdiagnosed or attributed to other causes.

Mechanism uncertainty. The rodent C-cell finding has not been mechanistically explained in a way that rules out a smaller, harder-to-detect effect in humans. Sub-clinical C-cell hyperplasia could exist in human users without producing detectable cancer in available study windows.

Class breadth. The contraindications apply uniformly across the GLP-1 class. Patients sometimes switch between agents, which means class-wide vigilance is appropriate even if individual molecules differ in their toxicology profiles.

These arguments justify continued post-marketing surveillance and adherence to contraindications. They do not justify avoiding semaglutide for patients who meet indications and have no contraindications. The reasonable position is informed use with respect for the boxed warning, not avoidance based on fear.

FAQ

Does Ozempic cause cancer? No established evidence shows Ozempic causes cancer in humans at typical clinical doses. The boxed warning reflects rodent findings that have not been confirmed in human populations.

Why does Ozempic have a black box warning for thyroid cancer? Rats and mice given semaglutide developed thyroid C-cell tumors, including medullary thyroid carcinoma. The FDA required the warning out of caution.

Has anyone gotten thyroid cancer from Ozempic in real life? Cases have been reported in FAERS but cannot establish causation. Large epidemiologic studies have not found a statistically significant increase in thyroid cancer overall among GLP-1 users.

What about pancreatic cancer and Ozempic? Early signals have not held up under repeated rigorous study. The current weight of evidence is reassuring.

Who should not take Ozempic because of cancer risk? Patients with personal or family history of medullary thyroid carcinoma, patients with multiple endocrine neoplasia type 2, and patients with an unexplained thyroid mass.

Does the cancer risk apply to compounded semaglutide? The active molecule is the same. Whatever the cancer risk profile of semaglutide proves to be, it applies to both branded Ozempic and properly compounded semaglutide.

Are there cancers Ozempic might reduce? Possibly. Obesity is a risk factor for at least 13 cancers, and weight loss reduces some of these risks. Observational analyses suggest GLP-1 users may have lower rates of obesity-related cancers.

How long do I need to take Ozempic to develop cancer risk? No clear answer. Continued monitoring is part of why long-term post-marketing surveillance exists.

Should I get screened for thyroid cancer while on Ozempic? Routine screening is not recommended for asymptomatic patients. Report new neck lumps, persistent hoarseness, or trouble swallowing.

Does the cancer warning apply to Wegovy too? Yes. Wegovy is semaglutide at a higher dose and carries the same boxed warning and contraindications.

What about other hormone-sensitive cancers? Current evidence does not link semaglutide to breast, prostate, or other hormone-sensitive cancers. Patients with these cancer histories should still discuss with their oncologist.

Related guides

• Does Zepbound Cause Cancer? Reading the Boxed Warning Against the Tirzepatide Evidence Base
• Does Ozempic Cause Hair Loss? What the Trial Data Actually Shows
• Is Ozempic Facing a $2 Billion Lawsuit? Separating the Headline From the Filings
• Has Anyone Gotten Thyroid Cancer From Ozempic? What the Cases and the Studies Actually Show
• How Ozempic Affects Anxiety: The Emerging Evidence
• Is Ozempic Safe Long-Term? The Honest Answer From the Current Evidence Base

Sources

1. FDA. Ozempic Prescribing Information (Boxed Warning and Contraindications). 2024 update.
2. Wang Y et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Thyroid Cancer. JAMA. 2024.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023.
5. Bjerre Knudsen L et al. Glucagon-like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-cells Causing Calcitonin Release and C-cell Proliferation. Endocrinology. 2010.
6. Bezin J et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023.
7. Egan AG et al. Pancreatic Safety of Incretin-Based Drugs: FDA and EMA Assessment. New England Journal of Medicine. 2014.
8. Pi-Sunyer X et al. Liraglutide Effect and Action in Diabetes (LEAD) Trial Extension Cancer Outcomes. Diabetes, Obesity and Metabolism. 2019.
9. Lauby-Secretan B et al. Body Fatness and Cancer: Viewpoint of the IARC Working Group. New England Journal of Medicine. 2016.
10. American Diabetes Association. Standards of Care in Diabetes 2025.
11. Endocrine Society. Clinical Practice Guideline on Pharmacotherapy for Obesity. 2024.
12. European Medicines Agency. Semaglutide Periodic Safety Update Reports. 2023-2025.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed clinicians and U.S. pharmacies. We do not provide direct oncology or endocrinology care. The information in this article is general and not a substitute for individualized clinical evaluation.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by state-licensed 503A pharmacies in response to individual prescriptions. The FDA boxed warning that applies to branded Ozempic also applies to compounded semaglutide because the active molecule is the same.

Results Disclaimer. Cancer risk statements summarize human epidemiologic and trial data available as of May 2026. Long-latency effects of any medication may not be fully visible in current data. Continued post-marketing surveillance is ongoing.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with Novo Nordisk, Eli Lilly, the FDA, the EMA, or any professional society named here.